MediPoint: Cardiac Rhythm Management – Global Analysis and Market Forecasts

Cardiac rhythm management (CRM) comprises any method of treatment aimed at regulating the heart’s rhythm, including medication, medical devices, and occasionally surgery. There can be a number of reasons why CRM is needed, all of which generally involve malfunctions of the heart’s electrical system, and are related to cardiac dyssynchrony. While medication can be effective in mild to moderate cases, patients with more severe conditions must turn to device use or surgical intervention in order to receive the therapy they require. Over the years, CRM device treatment has become less invasive, and significant advances in pacing and pulse generator technology have enabled effective long-term device therapy with limited complications.

Scope

Overview of arrhythmias, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.

Annualized Cardiac Rhythm Management (CRM) market revenue, annual cost of disease and adoption pattern data from 2010-2012 and forecast for eight years to 2020.

Key topics covered include strategic competitor assessment, next-generation technologies, market characterization, identification of unmet needs, reimbursement considerations, and implications for CRM market growth globally.

Pipeline analysis: comprehensive data split across different stages of development, emerging trends and mechanisms of support under development, including investigation of energy harvesting batteries, telemetry, and cardiac resynchronization therapy devices.

Analysis of the current and future market competition in the global Pacemaker (PM), Implantable Cardioverter-Defibrillator (ICD), Cardiac Resynchronization Therapy Pacemaker (CRT-P) and Cardiac Resynchronization Therapy Defibrillator (CRT-D) markets, as well as insightful review of the key industry drivers, opportunities, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

Around the world, dual-chamber pacemakers and ICDs are increasingly popular, which is one of the major factors in driving up the costs of the devices. (Q).What is the breakdown of single- and dual-chamber pacemakers and ICDs in each country? (Q).How will this change in the coming years?

Cardiac resynchronization therapy (CRT) is on the rise globally, and while the market is largely underpenetrated as of now, CRT devices are expected to experience significant adoption during the forecast period. (Q).Which countries are utilizing the devices now? (Q).How often will the devices be used in the future? (Q).What do Key Opinion Leaders think of these biventricular products?

Changing demographics are driving device implantation. (Q).How will risk factors including obesity, hypertension and diabetes affect the global CRM market?

Several major players in the market have already developed next-generation features. (Q).What are the most important product features and designs surgeons like about current systems? (Q).What features would they like to see in future product iterations? (Q).How will the introduction of energy-harvesting and leadless devices impact conventional device sales?

Device reprocessing and recycling is increasingly popular. (Q).What do patients think of reusing devices? (Q).How will this affect global CRM new-device sales?

Medtronic currently dominates the CRM market. (Q).What is their market share in the major global economies and which companies constitute the remainder of the market?

Companies are increasingly reliant on device adoption in emerging markets for continued sales growth. (Q).What percent of global profits are from emerging markets? (Q).How will this change in the future?

Diagnostic tools and techniques have improved greatly in recent years, driving CRM sales. (Q).How will diagnostic improvements continue to increase CRM market revenue?

Reasons to buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the CRM companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global Pacemaker and ICD market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CRM market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track device sales in the global PM, ICD, CRT-P, and CRT-D markets from 2010-2020.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

Biotronik

Boston Scientific Corporation

Impulse Dynamics

Medtronic, Inc.

Sorin Group

St. Jude Medical

Hadasit Medical Research Services

Endurance Rhythm

MicroPort Scientific

Kenergy, Inc.

EBR Systems ...

Biotronik

Boston Scientific Corporation

Impulse Dynamics

Medtronic, Inc.

Sorin Group

St. Jude Medical

Hadasit Medical Research Services

Endurance Rhythm

MicroPort Scientific

Kenergy, Inc.

EBR Systems, Inc.

SmartWave Medical

CardiaLen, Inc.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 ...

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Disease Overview

3.1 Anatomy and Physiology

3.1.1 Risk Factors

3.1.2 Etiology

3.2 Pathophysiology

3.2.1 Cardiac Arrhythmias

3.3 Clinical Presentation

3.3.1 Symptoms

3.4 Diagnosis

3.4.1 Blood and Urine Diagnostic Procedures

3.4.2 Electrocardiography-Based Diagnostic Procedures

3.4.3 Computerized Tomographic Angiography

3.4.4 Electrophysiological Testing

3.4.5 Electromechanical Wave Imaging

3.4.6 Echocardiography

3.4.7 Tilt-Table Testing

3.4.8 Diagnostic and Electrophysiological Studies

3.4.9 New York Heart Association Scale

3.4.10 American College of Cardiology Scale

3.4.11 Level of Evidence

3.5 Epidemiology

3.5.1 Prevalence

4 Industry Overview

4.1 Overview

4.2 Clinical Outcomes

4.2.1 Pacemakers

4.2.2 ICDs

4.2.3 CRT-Ps

4.2.4 CRT-Ds

4.3 Procedure Trends

4.3.1 Single-Chamber Devices More Popular than Dual-Chamber Devices in Developing

Economies

4.3.2 Cardiac Resynchronization Therapy Increasingly Popular Around the World

4.3.3 Device Reuse Programs to Transform Currently Wasted Resource

4.3.4 Hospital Market Growth

4.4 Market Access

4.4.1 US

4.4.2 Europe

4.4.3 Asia-Pacific

4.4.4 South America

4.4.5 Reimbursement Trends

4.5 Regulatory Issues/Recalls

4.5.1 Medtronic Pacemakers Recalled over Failure Risk, 2009

4.5.2 St. Jude Riata ICD Leads Recalled, 2011

4.6 Mergers and Acquisitions

4.6.1 Boston Scientific Acquires C.R. Bard’s Electrophysiology Business

4.6.2 Sorin Group Closes Further Investment and Option-to-Buy in Enopace Biomedical

4.7 Key Partnerships

4.7.1 Leti Forms Partnership with Sorin, TIMA, Cedrat Technologies, Tronics and EASII IC

4.7.2 St. Jude Medical to Invest in Nanostim

4.7.3 Sorin Group Signs Supply Agreement for Boston Scientific Corporation Lotus Valve

System

4.8 Economic Impact

4.8.1 Cost-Effectiveness of Pacemakers

4.8.2 Cost-Effectiveness of ICDs

4.8.3 Cost-Effectiveness of Cardiac Resynchronization Therapy

4.9 Market Drivers

4.9.1 Rapidly Increasing Patient Populations Suitable for Device Implantation to Drive Sales

4.9.2 Technological Advances and New Products in Pipeline to Drive Sales

4.9.3 Evolving Indications for Cardiac Rhythm Management Therapy

4.9.4 Imaging Guided Placement of Leads

4.9.5 Cost-Saving Benefits of Remote Home Monitoring

4.9.6 Growing Adoption of Device Use in Emerging Markets

4.9.7 Increased Primary Prevention Procedures

4.9.8 Increases in Implantation from Positive Clinical Trials

4.9.9 Antibacterial Envelopes to Reduce Rates of Complication and Increase Device Safety

4.9.10 Strong Portfolio of Pipeline Products from Key Players to Drive Future Growth of the

Market

4.9.11 Leadless Technology Eliminates Lead-Related Complications

4.9.12 Diagnostic Rate Improvements Expected to Drive CRM Device Sales

4.9.13 Increased Device Implantation in Pediatrics

4.10 Market Barriers

4.10.1 US Healthcare Reform May Impact US CRM Market Growth Adversely

4.10.2 Increased Emphasis on Value-Based Payment Programs through Medicare and Cost-

Effectiveness Research to Cause Competitive Pricing Pressure

4.10.3 Innovative and Next-Generation Drug Therapy May Pose a Challenge to CRM Devices

in the Future

4.10.4 Slow Adoption of Remote Patient Monitoring Could Restrain Market Growth

4.10.5 Lacking Reimbursement for Costly Devices in Emerging Markets

4.10.6 Inconsistencies between Various Guidelines Affects Treatment

4.10.7 Inappropriate Shock Rates May Thwart Potential CRM Patients

4.10.8 Patient Education to Increase Awareness and Device Adoption

4.10.9 Declining Average Selling Prices to Adversely Affect CRM Product Revenues

5 Competitive Assessment

5.1 Overview

5.2 Global Market Share

5.2.1 Pacemaker and CRT-P Market Company Share Globally

5.2.2 ICD and CRT-D Market Company Share Globally

5.3 Regional Market Share

5.3.1 Pacemaker and CRT-P Market Company Share in the US

5.3.2 ICD and CRT-D Market Company Share in the US

5.3.3 Pacemaker and CRT-P Company Share in Europe

5.3.4 ICD and CRT-D Market Company Share in Europe

5.3.5 Pacemaker and CRT-P Market Company Share in Emerging Markets

5.3.6 ICD and CRT-D Market Company Share in Emerging Markets

5.3.7 Pacemaker and CRT-P Market Company Share in Japan

5.3.8 ICD and CRT-D Market Company Share in Japan

6 Unmet Needs

6.1 Overview

6.2 Leads and Electrode Development

6.2.1 MRI-Compatible Generators and Leads

6.2.2 Single-Lead Systems with Atrial Diagnostics

6.3 Power-Supplying Batteries

6.4 Energy-Harvesting Batteries

6.5 Rates of Infection

7 Pipeline Products

7.1 Overview

7.2 Pipeline Products by Phase in Development

7.3 Pacemaker and CRT-P Product Profiles

7.3.1 Aortic Pacemaker (Hadasit Medical Research Services & Development Ltd.)

7.3.2 Cardiac Energy Harvesting Pacemaker (University of Michigan)

7.3.3 Endurance Microgenerator (Endurance Rhythm)

7.3.4 Implantable Dual-Chamber Pacemaker (MicroPort Scientific)

7.3.5 Unconditional MRI-Compatible Implantable Pacemaker (Kenergy, Inc.)

7.3.6 Tissue-Engineered Autonomous Pacemaker (Duke University)

7.3.7 Wireless Cardiac Stimulation Device (EBR Systems, Inc.)

7.4 ICD and CRT-D Product Profiles

7.4.1 Atrial Defibrillator (SmartWave Medical Ltd.)

7.4.2 CardiaLen (CardiaLen, Inc.)

7.4.3 Chronicle (Medtronic)

7.5 Clinical Trials to Watch

7.5.1 Overview

7.5.2 SELECT-LV Trial of WiCS-LV System (EBR Systems, Inc.)

7.5.3 MultiPoint Pacing Clinical Trial of Quadra Assura CRT-D (Medtronic)

7.5.4 MADIT-ASIA Trial with Invive CRT-P (Boston Scientific)

7.5.5 MultiPoint Pacing IDE Study of Promote Quadra (St. Jude Medical)

7.5.6 Post Approval Study of S-ICD System (Boston Scientific)

7.5.7 ProMRI Study of the Evia/Entovis Pacemaker System

7.5.8 MIRACLE EF Clinical Study of Consulta CRT-P (Medtronic)

8 Current and Future Players

8.1 Overview

8.2 Trends in Corporate Strategy

8.3 Biotronik

8.3.1 Overview

8.3.2 Portfolio Evaluation

8.3.3 Commercial Positioning

8.3.4 Company SWOT Analysis

8.4 Boston Scientific

8.4.1 Overview

8.4.2 Portfolio Evaluation

8.4.3 Commercial Positioning

8.4.4 Company SWOT Analysis

8.5 Impulse Dynamics

8.5.1 Overview

8.5.2 Portfolio Evaluation

8.5.3 Commercial Positioning

8.5.4 Company SWOT Analysis

8.6 Medtronic

8.6.1 Overview

8.6.2 Portfolio Evaluation

8.6.3 Marketed Products

8.6.4 Additional Products

8.6.5 Commercial Positioning

8.6.6 Company SWOT Analysis

8.7 Sorin Group

8.7.1 Overview

8.7.2 Portfolio Evaluation

8.7.3 Marketed Products

8.7.4 Commercial Positioning

8.7.5 Company SWOT Analysis

8.8 St. Jude Medical

8.8.1 Overview

8.8.2 Portfolio Evaluation

8.8.3 Marketed Products

8.8.4 Commercial Positioning

8.8.5 Company SWOT Analysis

9 Market Outlooks and Forecasts

9.1 Market Outlooks and Forecasts by Market Segment

9.1.1 Pacemaker Market by Device Type

9.1.2 ICD Market by Device Type

9.1.3 CRT-P Market

9.1.4 CRT-D Market

9.2 Market Outlooks and Forecasts by Geography

9.2.1 US

9.2.2 France

9.2.3 Germany

9.2.4 Italy

9.2.5 Spain

9.2.6 UK

9.2.7 Japan

9.2.8 China

9.2.9 India

9.2.10 Brazil

10 Appendix

10.1 Bibliography

10.2 Abbreviations

10.3 Report Methodology

10.3.1 Overview

10.3.2 Coverage

10.3.3 Secondary Research

10.3.4 Forecasting Methodology

10.3.5 Primary Research – Key Opinion Leader Interviews

10.3.6 Expert Panel Validation

10.4 Physicians and Specialists Included in this Study

10.5 About the Authors

10.5.1 Analysts

10.5.2 Global Head of Healthcare

10.6 About MediPoint

10.7 About GlobalData

10.8 Disclaimer

List of Tables

Table 1: New York Heart Association Scale

Table 2: American College of Cardiology Scale

Table 3: Level of Evidence

Table 4: Prevalent Cases of Congestive ...

Table 1: New York Heart Association Scale

Table 2: American College of Cardiology Scale

Table 3: Level of Evidence

Table 4: Prevalent Cases of Congestive Heart Failure, All Markets, Ages =45 Years, Men and Women (n),

2012–2019

Table 5: Pacemaker Implantation Classification Guideline

Table 6: Patient Post-Operative Condition with ICD Implantation, 2012

Table 7: Level of Evidence Guidelines

Table 8: Single-Chamber Pacemakers versus Dual-Chamber Pacemakers, Sales Volume Comparison, by

Country, 2012

Table 9: Single-Chamber ICDs versus Dual-Chamber ICDs, Sales Volume Comparison, by Country, 2012

Table 10: CRT-P versus Conventional Pacemakers, Sales Volume Comparison, by Country, 2012

Table 11: CRT-D versus Conventional ICD Products, Sales Volume Comparison, by Country, 2012

Table 12: Healthcare Expenditure by Payer (%) and Healthcare Expenditure per Capita ($), Global, 2011

Table 13: Medicare Standardized Payment Rates for Hospitals for Pacemaker/CRT-P Implantation

Table 14: Medicare Standardized Payment Rates for Hospitals for Pacemaker/CRT-P Replacement

Table 15: Medicare Standardized Payment Rates for Hospitals for ICD/CRT-D Implantation

Table 16: Medicare Standardized Payment Rates for Hospitals for ICD/CRT-D Replacement

Table 17: Percentage of Population Aged 65 Years and Older, by Country, 2005–2015

Table 18: Percentage of Smoking Population by Country (%), Global, 2010

Table 19: Percentage of Overweight and Obese Population (Aged 15 Years and Above), by Country, 2012

Table 20: Diabetes Prevalence Rates by Region (%), 20–79 Years, Global, 2007 & 2010

Table 21: Percentage of Hypertensive Population Aged 25 Years and Above (%), Global, 2010

Table 22: Technological Innovations, Cardiac Rhythm Management Devices

Table 23: Benefits of Quadripolar Lead Technology

Table 24: Updated Cardiac Resynchronization Therapy Guidelines

Table 25: Emerging Market Contribution, Global, 2009–2012

Table 26: Percent Primary Prevention Implantation by Country (%), ICD/CRT-D, Global, 2012

Table 27: Primary Prevention Cases by Country (%), ICD, Global, 2012

Table 28: Barriers in Access to Quality Healthcare Leading to Disparities in CRM Treatment

Table 29: Average Selling Price ($) Comparison, by Country, 2012

Table 30: Pacemaker and CRT-P Market, Global, Company Share (%), 2012

Table 31: ICD and CRT-D Market, Global, Company Share (%), 2012

Table 32: Pacemaker and CRT-P Market, US, Revenue ($) and Company Share (%), 2012

Table 33: ICD and CRT-D Market, US, Revenue ($) and Company Share (%), 2012

Table 34: Pacemaker and CRT-P Market, Europe, Revenue ($) and Company Share (%), 2012

Table 35: ICD and CRT-D Market, Europe, Revenue ($) and Company Share (%), 2012

Table 36: Pacemaker and CRT-P Market, Emerging Markets, Revenue ($) and Company Share (%), 2012

Table 37: ICD and CRT-D Market, Emerging Markets, Revenue ($) and Company Share (%), 2012

Table 38: Pacemaker and CRT-P Market, Japan, Revenue ($) and Company Share (%), 2012

Table 39: ICD and CRT-D Market, Japan, Revenue ($) and Company Share (%), 2012

Table 40: Product Profile – Aortic Pacemaker

Table 41: Product Profile – Cardiac Energy Harvesting Pacemaker

Table 42: Product Profile – Endurance Microgenerator

Table 43: Product Profile – MicroPort Pacemaker

Table 44: Product Profile – Kenergy Pacemaker

Table 45: Product Profile – Tissue-Engineered Autonomous Pacemaker

Table 46: Product Profile – Wireless Cardiac Stimulation Device

Table 47: Product Profile – Atrial Defibrillator

Table 48: Product Profile – CardiaLen

Table 49: Product Profile – Chronicle

Table 50: Clinical Trial for WiCS-LV System

Table 51: Clinical Trial for Quadra Assura CRT-D

Table 52: Clinical Trial for Invive CRT-P

Table 53: MultiPoint Pacing IDE Study for Promote Quadra

Table 54: Post Approval Study of S-ICD System

Table 55: ProMRI Study of the Evia/Entovis Pacemaker System

Table 56: MIRACLE EF Clinical Study of Consulta CRT-P

Table 57: Company Profile – Biotronik

Table 58: Product Profile – Cylos 990

Table 59: Product Profile – Effecta

Table 60: Product Profile – Evia/Entovis

Table 61: Product Profile – Estella

Table 62: Product Profile – Stratos

Table 63: Product Profile – Ilesto 7

Table 64: Product Profile – Lumax

Table 65: Biotronik SWOT Analysis, 2012

Table 66: Company Profile – Boston Scientific

Table 67: Product Profile – Advantio

Table 68: Product Profile – Altrua

Table 69: Product Profile – Cognis

Table 70: Product Profile – Energen

Table 71: Product Profile – Incepta

Table 72: Product Profile – Ingenio

Table 73: Product Profile – Invive

Table 74: Product Profile – Punctua

Table 75: Product Profile – S-ICD System 2.0

Table 76: Product Profile – Teligen

Table 77: Boston Scientific SWOT Analysis, 2012

Table 78: Company Profile – Impulse Dynamics

Table 79: Product Profile – Optimizer IVs

Table 80: Impulse Dynamics SWOT Analysis, 2012

Table 81: Company Profile – Medtronic

Table 82: Product Profile – Advisa

Table 83: Product Profile – Adapta

Table 84: Product Profile – Brava/Viva

Table 85: Product Profile – Consulta

Table 86: Product Profile – EnPulse

Table 87: Product Profile – EnRhythm

Table 88: Product Profile – Ensura MRI

Table 89: Product Profile – Evera

Table 90: Product Profile – Protecta

Table 91: Product Profile – Secura

Table 92: Product Profile – Syncra

Table 93: Product Profile – Revo

Table 94: Product Profile – Concerto

Table 95: Product Profile – EnTrust

Table 96: Product Profile – Maximo II

Table 97: Medtronic SWOT Analysis, 2012

Table 98: Company Profile – Sorin Group

Table 99: Product Profile – Esprit

Table 100: Product Profile – Paradym

Table 101: Product Profile – Reply 2000

Table 102: Sorin Group SWOT Analysis, 2012

Table 103: Company Profile – St. Jude Medical

Table 104: Product Profile – Accent

Table 105: Product Profile – Accent MRI

Table 106: Product Profile – Anthem

Table 107: Product Profile – Allure Quadra

Table 108: Product Profile – AnalyST Accel

Table 109: Product Profile – Assurity

Table 110: Product Profile – Current Accel

Table 111: Product Profile – Current Plus

Table 112: Product Profile – Ellipse

Table 113: Product Profile – Endurity

Table 114: Product Profile – Fortify Assura

Table 115: Product Profile – Fortify

Table 116: Product Profile – Microny

Table 117: Product Profile – Leadless Pacemaker

Table 118: Product Profile – Promote Plus

Table 119: Product Profile – Quadra Assura

Table 120: Product Profile – Unify Assura

Table 121: Product Profile – Unify Quadra

Table 122: Product Profile – Unify

Table 123: Product Profile – Zephyr

Table 124: St. Jude Medical SWOT Analysis, 2012

Table 125: Pacemaker Market, Global, Revenue ($m), 2010–2020

Table 126: ICD Market, Global, Revenue ($m), 2010–2020

Table 127: CRT-P Market, Global, Revenue ($m), 2010–2020

Table 128: CRT-D Market, Global, Revenue ($m), 2010–2020

Table 129: US Cardiac Rhythm Management Device Implantation

Table 130: Implantable Cardioverter-Defibrillators Patient Clinical History Breakdown (%), US, 2012

Table 131: Implanting Physician Training Status (%), US, 2012

Table 132: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, US, Revenue ($m),

2010–2020

Table 133: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, US, Revenue ($m), 2010–2020

Table 134: France Cardiac Rhythm Management Device Implantation

Table 135: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, France, Revenue ($m),

2010–2020

Table 136: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, France, Revenue ($m), 2010–2020

Table 137: Germany Cardiac Rhythm Management Device Implantation

Table 138: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Germany, Revenue ($m),

2010–2020

Table 139: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, Germany, Revenue ($m), 2010–2020

Table 140: Italy Cardiac Rhythm Management Device Implantation

Table 141: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Italy, Revenue ($m),

2010–2020

Table 142: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, Italy, Revenue ($m), 2010–2020

Table 143: Spain Cardiac Rhythm Management Device Implantation

Table 144: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Spain, Revenue ($m),

2010–2020

Table 145: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, Spain, Revenue ($m), 2010–2020

Table 146: UK Cardiac Rhythm Management Device Implantation

Table 147: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, UK, Revenue ($m),

2010–2020

Table 148: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, UK, Revenue ($m), 2010–2020

Table 149: Japan Cardiac Rhythm Management Device Implantation

Table 150: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Japan, Revenue ($m),

2010–2020

Table 151: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, Japan, Revenue ($m), 2010–2020

Table 152: China Cardiac Rhythm Management Device Implantation

Table 153: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, China, Revenue ($m),

2010–2020

Table 154: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, China, Revenue ($m), 2010–2020

Table 155: India Cardiac Rhythm Management Device Implantation

Table 156: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, India, Revenue ($m),

2010–2020

Table 157: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, India, Revenue ($m), 2010–2020

Table 158: Brazil Cardiac Rhythm Management Device Implantation

Table 159: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Brazil, Revenue ($m),

2010–2020

Table 160: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, Brazil, Revenue ($m), 2010–2020

List of Figures

Figure 1: Types of Arrhythmia

Figure 2: Generic Pacemaker Code

Figure 3: Guide for Pacemaker Implantation

Figure 4: Percent Dual-Chamber Pacemakers, by Country, 2010, 2013 ...

Figure 1: Types of Arrhythmia

Figure 2: Generic Pacemaker Code

Figure 3: Guide for Pacemaker Implantation

Figure 4: Percent Dual-Chamber Pacemakers, by Country, 2010, 2013, 2020

Figure 5: Dual-Chamber ICDs (%), by Country, 2009, 2013, 2020

Figure 6: CRT-P versus Conventional Pacemakers, Sales Volume Comparison, by Country, 2012

Figure 7: CRT-D versus Conventional ICD Products, Sales Volume Comparison, by Country, 2012

Figure 8: Patient and General Population Preferences for CRM Device Reuse, US

Figure 9: Healthcare Expenditure by Payer, Global, 2011

Figure 10: Percentage of Population Aged 65 Years and Above, by Country, 2005–2015

Figure 11: Diabetes Prevalence Rates, 20–79 Years, by Region, 2007–2010

Figure 12: Percentage of Hypertensive Population Aged 25 Years and Above (%), Global, 2010

Figure 13: Evaluating Effectiveness of Remote Home Monitoring

Figure 14: Emerging Market Contribution, Global, 2009–2012

Figure 15: Percent Primary Prevention Implantation by Country (%), ICD/CRT-D, Global, 2012

Figure 16: Primary Prevention Cases by Country (%), ICD, Global, 2012

Figure 17: Secondary Prevention Diagnosed Cases by Country (%), ICD, Global, 2012

Figure 18: Diagnosed VT & VF Cases Receiving ICD by Country (%), ICD, Global, 2012

Figure 19: Average Selling Price ($) Comparison, by Country, 2012

Figure 20: Pacemaker and CRT-P Market, Global, Company Share (%), 2012

Figure 21: ICD and CRT-D Market, Global, Company Share (%), 2012

Figure 22: Pacemaker and CRT-P Market, US, Company Share (%), 2012

Figure 23: ICD and CRT-D Market, US, Company Share (%), 2012

Figure 24: Pacemaker and CRT-P Market, Europe, Company Share (%), 2012

Figure 25: ICD and CRT-D Market, Europe, Company Share (%), 2012

Figure 26: Pacemaker and CRT-P Market, Emerging Markets, Company Share (%), 2012

Figure 27: ICD and CRT-D Market, Emerging Markets, Company Share (%), 2012

Figure 28: Pacemaker and CRT-P Market, Japan, Company Share (%), 2012

Figure 29: ICD and CRT-D Market, Japan, Company Share (%), 2012

Figure 30: CRM Pipeline Products by Phase in Development

Figure 31: Pacemaker Market by Device Type, Global, Revenue ($m), 2010–2020

Figure 32: Pacemaker Market, Global, Revenue ($m), 2010–2020

Figure 33: CRT-P Market, Global, Revenue ($m), 2010–2020

Figure 34: CRT-D Market, Global, Revenue ($m), 2010–2020

Figure 35: Cardiac Resynchronization Therapy Implantation, US, by Age (%), 2011

Figure 36: Cardiac Rhythm Management Implantation by Sex (%), US, 2012

Figure 37: Pacemaker Implantation by Payer, US, 2012

Figure 38: Pacemaker Implantation by Hospital Size, US, 2012

Figure 39: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, US, Revenue ($m),

2010–2020

Figure 40: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, US, Revenue ($m), 2010–2020

Figure 41: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, France, Revenue ($m),

2010–2020

Figure 42: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, France, Revenue ($m), 2010–2020

Figure 43: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Germany, Revenue ($m),

2010–2020

Figure 44: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, Germany, Revenue ($m), 2010–2020

Figure 45: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Italy, Revenue ($m),

2010–2020

Figure 46: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, Italy, Revenue ($m), 2010–2020

Figure 47: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Spain, Revenue ($m),

2010–2020

Figure 48: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, Spain, Revenue ($m), 2010–2020

Figure 49: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, UK, Revenue ($m),

2010–2020

Figure 50: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, UK, Revenue ($m), 2010–2020

Figure 51: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Japan, Revenue ($m),

2010–2020

Figure 52: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, Japan, Revenue ($m), 2010–2020

Figure 53: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, China, Revenue ($m),

2010–2020

Figure 54: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, China, Revenue ($m), 2010–2020

Figure 55: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, India, Revenue ($m),

2010–2020

Figure 56: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, India, Revenue ($m), 2010–2020

Figure 57: Pacemakers and Cardiac Resynchronization Therapy Pacemakers, Brazil, Revenue ($m),

2010–2020

Figure 58: Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Defibrillators

Market, Brazil, Revenue ($m), 2010–2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports